Logo
x

Search

Subscribe Now

AbbVie

AbbVie Receives EC’s Conditional Marketing for Tepkinly (Epcoritamab) to R/R Follicular Lymphoma (FL)

AbbVie Receives EC’s Conditional Marketing for Tepkinly (Epcoritamab) to R/R Follicular Lymphoma (FL)

  • August 22, 2024
AbbVie’s Skyrizi (Risankizumab) Receives the EC’s Approval to Treat Moderate to Severe Active Ulcerative Colitis

AbbVie’s Skyrizi (Risankizumab) Receives the EC’s Approval to Treat Moderate to Severe Active Ulcerative Colitis

  • July 26, 2024
AbbVie Reports the Regulatory Submissions to the US FDA and EMA of Rinvoq (Upadacitinib) to Treat Giant Cell Arteritis (GCA)

AbbVie Reports the Regulatory Submissions to the US FDA and EMA of Rinvoq (Upadacitinib) to Treat Giant Cell Arteritis (GCA)

  • July 15, 2024
AbbVie’s Tepkinly (Epcoritamab) Gains the CHMP’s Positive Opinion to Treat R/R Follicular Lymphoma

AbbVie’s Tepkinly (Epcoritamab) Gains the CHMP’s Positive Opinion to Treat R/R Follicular Lymphoma

  • July 1, 2024
AbbVie Reports the Acquisition of Celsius Therapeutics

AbbVie Reports the Acquisition of Celsius Therapeutics

  • June 28, 2024
AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma

AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma

  • June 27, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.